Main Logo
  • About Us
    • Our Philosophy
    • The Industry and Us
  • Our Strategy
    • Our Technology
    • Key Applications
    • Clinical Programs
    • Preclinical Programs
    • Pipeline
    • Our Partnerships
  • Our Team
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Contact Us
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
    • In The News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Filings & Financials
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Management Team
  • Investor Resources
    • Contacts
    • Email Alerts
    • FAQs
    • Investor Fact Sheet
  • News

  • Press Releases
  • Email Alerts
  • In The News
Apr 18, 2022 4:05pm EDT

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

Mar 31, 2022 4:05pm EDT

Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022 5:10pm EDT

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call

Feb 23, 2022 8:31am EST

Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference

Feb 08, 2022 4:01pm EST

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

Jan 31, 2022 4:01pm EST

Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

Jan 27, 2022 8:30am EST

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

Jan 19, 2022 4:19pm EST

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

Jan 10, 2022 8:00am EST

Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid

Jan 05, 2022 4:05pm EST

Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference

  • Previous Pagearrow_back
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

  • Our philosophy
  • The Industry and Us

Our strategy

  • Our Technology
  • Key Applications
  • Clinical Programs
  • Preclinical Programs
  • Pipeline
  • Our Partnerships

Our Team

  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Contact Us

Investors

Follow Ensysce on social media:

  • /company/Ensyscebio
  • @Ensyscebio
  • /Ensyscebio